Products › CJC-1295 (no DAC)
Growth Hormone Axis

CJC-1295 without Drug Affinity Complex (Modified GRF 1-29)

A modified growth-hormone-releasing hormone (GHRH) analog, also known as Mod GRF 1-29, studied in preclinical research on GH secretagogue pathways.

CAS Number
863288-34-0
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Formula
C152H252N44O42
Molecular Weight
3367.9 g/mol
Purity
≥98% (HPLC)
Form
Lyophilized powder
Vial Content
10mg/10mg per vial (CJC-1295/Ipamorelin Blend)
Documentation
COA & HPLC Analysis
See our quality assurance & testing process ›

Overview

CJC-1295 without DAC — frequently referred to in the literature as Modified GRF (1-29), or Mod GRF 1-29 — is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH), modified at several positions to resist enzymatic degradation. Peptide Factory supplies this peptide as a lyophilized powder for laboratory research.

Research Background

Native GHRH(1-29) is rapidly degraded in circulation by dipeptidyl peptidase-4 (DPP-4) and other proteases. The amino acid substitutions in CJC-1295 (no DAC) were designed to confer resistance to this degradation, extending the peptide’s research half-life relative to native GHRH while preserving its receptor-binding profile at the GHRH receptor (GHRHR) on pituitary somatotroph cells.

Studied Applications

Laboratory and preclinical research involving CJC-1295 (no DAC) has focused on:

  • GH secretagogue pathway research — in vitro pituitary cell culture and in vivo animal models have been used to characterize dose-response relationships between GHRH receptor agonists and growth hormone/IGF-1 axis activity.
  • Synergy research with ghrelin-mimetic peptides — studies combining GHRH analogs with growth hormone secretagogues (e.g., Ipamorelin) have investigated pulsatile GH release mechanisms in animal models.
  • Pharmacokinetic comparison research — used as a shorter-acting reference compound against DAC-modified and other long-acting GHRH analogs in half-life and receptor-occupancy studies.

These findings reflect laboratory and animal research; no dosing or human-use guidance is provided.

Storage & Handling

Store lyophilized CJC-1295 (no DAC) at -20°C, protected from light and moisture. See our storage and handling guidance for reconstitution protocols.

References

  • Teichman, S. L. et al. “Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295.” J. Clin. Endocrinol. Metab. research literature.
  • Ionescu, M. & Frohman, L. A. GHRH analog pharmacokinetics research.
  • Walker, R. F. GHRH-based secretagogue research review.

For Research Use Only — Not for Human Consumption.

Frequently Asked

What distinguishes CJC-1295 without DAC from the DAC version?
The 'no DAC' variant lacks the Drug Affinity Complex modification that extends plasma half-life via albumin binding. It is a shorter-acting GHRH(1-29) analog, commonly referred to as Mod GRF 1-29 in the research literature.
Does CJC-1295 (no DAC) act directly on the pituitary?
In research models, it is studied as a GHRH receptor agonist, meaning its research-observed effects on growth hormone secretion are mediated through pituitary GHRH receptors rather than direct hormone replacement.

Related Products

For Research Use Only — Not for Human Consumption